Propranolol 2

Phase 1Small molecule

UUniversity of Utah

Propranolol 2 is one of 35 small molecule programs targeting Fibromyalgia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibromyalgiaActive, not recruiting

FibromyalgiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

152 competitors in Fibromyalgia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Phase 3

1 3

Xyrem

Jazz Pharmaceuticals

Phase 3

1 4

Lexapro

AbbVie

Phase 3

1 5

Neurontin

VViatris Specialty LLC

Phase 3

3 6

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 7

Ultram

WWim Janssens

Phase 3

1 8

DS-5565

Daiichi Sankyo

Phase 3

4 9

Genotropin

EMD Serono

Phase 3

—10

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fibromyalgia1 trial

Propranolol for Treating Fibromyalgia Pain

Terminated·UUniversity of Utah·Phase 1·NCT03029845·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Propranolol 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propranolol 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propranolol 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Utah

Propranolol 2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fibromyalgia1 trial

References

Drug Info

Quick Facts

Related News